Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Establishment of biomarkers to predict response to glucocorticoids for thyroid eye disease by DIA proteome analysis.

ABSTRACT: The standard treatment for thyroid eye disease is glucocorticoid administration, however its response varies from case to case. In recent years, treatment of thyroid eye disease has evolved dramatically, and the efficacy of several agents is being demonstrated. If steroid resistance is identified prior to treatment, the quality of care can be improved by using other agents as first-line therapy. We performed DIA proteome analysis on pretreatment sera of glucocorticoids response and resistance patients to search for candidate biomarkers of therapeutic response. Sera from healthy subjects and those with Graves' disease without thyroid eye disease are also analyzed together as controls.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Kazuhiko Matsuzawa

PROVIDER: PXD061741 | JPOST Repository | Thu Mar 12 00:00:00 GMT 2026

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20230128_103237_22P26130001_Report.xls	Xls
	22P26130001.raw	Raw
	22P26130002.raw	Raw
	22P26130003.raw	Raw
	22P26130004.raw	Raw

Items per page:

1 - 5 of 19

Similar Datasets

Using mass spectrometry-based proteomics to identify candidate blood-based markers of cardiomyopathy in the southern sea otter (Enhydra lutris nereis)

Project description:Cardiomyopathy is a heart muscle disease and diagnosis relies on radiography and echocardiography, while blood-based markers are lacking. Development of a non-invasive test would be useful when imaging is not possible (e.g., prenatal diagnosis). In southern sea otters (Enhydra lutris nereis), cardiomyopathy is a prevalent cause of mortality and antemortem diagnosis is challenging. Sea otters requiring clinical care are at significant anesthetic risk if cardiomyopathy is present. A blood-based assay would improve triage decisions, case management, and treatment protocols to safeguard against co-morbidities. With support from the Oiled Wildlife Care Network, we analyzed undepleted sea otter serum using mass spectrometry-based proteomics. Though the larger sample set included 63 sera (that included a validation set of 22 sera with class labels blinded to the data collector), we a priori compared only samples from wild otters. Additionally, we generated proteomic data for four heat tissues with paired sera. These results demonstrate the utility of proteomic analysis, offer a glimpse into the sea otter proteome, and serve as a reference data set for relative protein abundance in sera and cardiac tissue.

2021-12-22 | PXD030595 | Pride

Gastorointestinal Cancer Clinical Cohorts

Project description:<p>Comprehensive genomic profiling of colon adenocarcinomas has revealed multiple recurrent alterations that may inform new treatment strategies. Clinical trials of these agents are ongoing, although the mechanisms of response and resistance to these agents are not well characterized. The goal of this study is to perform comprehensive profiling of pre-treatment and post-resistance tumor and germline samples obtained from patients with colon cancer who receive these agents by carrying out whole exome sequencing and RNA sequencing, and to use these data to identify mechanisms of response and resistance.</p>

| phs000803 | dbGaP

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [T-47D cell line ChIP-seq]

Project description:The role of the androgen receptor (AR) in estrogen receptor alpha (ER) positive breast cancer is controversial, constraining implementation of AR-directed therapies. Using a diverse, clinically relevant panel of cell-line and patient-derived models, we demonstrate that AR activation, not suppression, exerts potent anti-tumor activity in multiple disease contexts, including resistance to standard-of-care ER and CDK4/6 inhibitors. Importantly, AR agonists combined with standard-of-care agents enhanced therapeutic responses. Mechanistically, agonist activation of AR altered the genomic distribution of ER and essential co-activators (p300, SRC-3), resulting in repression of ER-regulated cell cycle genes and up-regulation of AR target genes, including known tumor suppressors. A gene signature of AR activity positively predicted disease survival in multiple clinical ER+ breast cancer cohorts. These findings provide unambiguous evidence that AR has a tumor suppressor role in ER+ breast cancer and support AR agonism as the optimal AR-directed treatment strategy, revealing a rational therapeutic opportunity.

2021-01-18 | GSE129929 | GEO

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [ZR-75-1 cell line AR, ER, and H3K27ac ChIP-seq]

2021-01-18 | GSE123767 | GEO